参考文献/References:
[1] Ruoslahti E. The RGD story:a personal account. Matrix Biol[J]. 2003, 22(6):459-465.
[2] Wickham, TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachement[J]. Cell, 1993, 73(2):309-319.
[3] Marcinkiewicz C. Functional characteristic of snake venom disintegrins:potential therapeutic implication[J]. Curr Pharm Des, 2005, 11(7):815-827.
[4] Ahmed N, Riley C, Rice G, et al. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment[J]. Clin Exp Metastasis, 2005, 22(5):391-402.
[5] Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha (v)beta(3) integrin binding peptides in a nude mouse model[J]. Cancer Res, 2002, 62(21):6146-6151.
[6] Zheng DQ, Woodard AS, Fornaro M, et al. Prostatic carcinoma cell migration via alpha (v) beta (3) integrin is modulated by focal adhesion kinase pathway[J]. Cancer Res, 1999, 59(2):1655-1664.
[7] Vonlaufen A, Wiedle G, Borisch B, et al. Integrin αvβ3 expression in colon carcinoma correlates with survival[J]. Mod Pathol, 2001, 14(11):1126-1131.
[8] Kanamori M, Kawaguchi T, Berger MS, et al. Intracranial microenvironment reveals independent opposing functions of host alphaV beta3 expression on glioma growth and angiogenesis[J]. J Biol Chem, 2006, 281(48):37256-37264.
[9] Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities[J]. Prep Biochem Biotechnol, 2002, 32(4):363-380.
[10] Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD, et al. Solution stability of linear vs. cyclic RGD peptide[J]s. J Pept Res, 1999, 53(5):530-541.
[11] Richards J, Miller M, Abend J, et al. Engineered fibronectin type Ⅲ domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphav beta3 integrin[J]. J Mol Biol, 2003, 326(5):1475-1488.
[12] Mitra A, Mulholland J, Nan A, et al. Targeting tumor angiogenic vasculature using polymer-RGD conjugates[J]. J Control Release, 2005, 102(1):191-201.
[13] Chen X, Tohme M, Park R, et al. Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide[J]. Mol Imaging, 2004, 3(2):96-104.
[14] Chen X, Park R, Tohme M, et al. Micro PET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F-and 64Cu-labeled RGD peptide[J]. Bioconjug Chem, 2004, 15(1):41-49.
[15] Chen X, Park R, Hou Y, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide[J]. Eur J Nucl Med Mol Imaging, 2004, 31(8):1081-1089.
[16] Chen X, Park R, ShahinianAH, et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation[J]. Nuel Med Biol, 2004, 31(1):11-19.
[17] Su ZF, Liu G, Gupta S, et al. In vitro and in vivo evaluation of a Technetiun-99m-labeled cyclic RGD peptide as a specific marker of alpha(v)beta(3)integrin for tumor imaging[J]. Bioconjug Chem, 2002, 13(3):561-570.
[18] Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography[J]. Cancer Res, 2001, 61(5):1781-1785.
[19] Bernard B, Capello A, van Hagen M, et al. Radiolabeled RGDDTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy[J]. Cancer Biother Radiopharm, 2004, 19(2):173-180.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]陈素芸.放射性核素标记RGD多肽在整合素受体显像中的应用[J].国际放射医学核医学杂志,2007,31(3):129.
CHEN Su-yun.Application of radiolabeled RGD peptides in imaging of integrin receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):129.